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Elevated FGF23 Levels in Mice 
Lacking the Thiazide-Sensitive NaCl 
cotransporter (NCC)
Ganesh Pathare1,2,3, Manuel Anderegg  1,2,3, Giuseppe Albano1,2,3, Florian Lang  4,5 &  
Daniel G. Fuster1,2,3
Fibroblast growth factor 23 (FGF23) participates in the orchestration of mineral metabolism by 
inducing phosphaturia and decreasing the production of 1,25(OH)2D3. It is known that FGF23 release 
is stimulated by aldosterone and extracellular volume depletion. To characterize this effect further in a 
model of mild hypovolemia, we studied mice lacking the thiazide sensitive NaCl cotransporter (NCC). 
Our data indicate that NCC knockout mice (KO) have significantly higher FGF23, PTH and aldosterone 
concentrations than corresponding wild type (WT) mice. However, 1,25(OH)2D3, fractional phosphate 
excretion and renal brush border expression of the sodium/phosphate co-transporter 2a were not 
different between the two genotypes. In addition, renal expression of FGF23 receptor FGFR1 and the 
co-receptor Klotho were unaltered in NCC KO mice. FGF23 transcript was increased in the bone of NCC 
KO mice compared to WT mice, but treatment of primary murine osteoblasts with the NCC inhibitor 
hydrochlorothiazide did not elicit an increase of FGF23 transcription. In contrast, the mineralocorticoid 
receptor blocker eplerenone reversed excess FGF23 levels in KO mice but not in WT mice, indicating that 
FGF23 upregulation in NCC KO mice is primarily aldosterone-mediated. Together, our data reveal that 
lack of renal NCC causes an aldosterone-mediated upregulation of circulating FGF23.
Fibroblast growth factor‐23 (FGF23) is a bone derived phosphate and 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) 
regulating hormone which is secreted by osteoblasts and osteocytes1. Fibroblast growth factor receptor 1 
(FGFR1) is the principal mediator of the effects of FGF232,3. Furthermore, α-Klotho, an antiaging protein, binds 
to FGFR1 and increases the affinity of FGFR1 for FGF234. In the kidney, circulating FGF23 reduces phosphate 
reabsorption from primary urine through a direct downregulation of the sodium phosphate co‐transporter 2 a 
(NaPi2a) in renal proximal tubular epithelial cells5. In addition, FGF23 inhibits the formation of 1,25(OH)2D3 
by down-regulating renal 1α hydroxylase (Cyp27b1) and stimulating 1,25(OH)2D3 inactivation by upregula-
tion of 25-hydroxyvitamin D 24-hydroxylase (Cyp24a1)6. Increased FGF23 levels may be pathophysiologically 
relevant7,8, as they are correlated with accelerated disease progression and increased morbidity and mortality in 
several clinical disorders including cardiac failure9,10, acute renal failure11, chronic kidney disease4,10,12, diabetic 
nephropathy13 and hepatic failure14. FGF23 levels rise during chronic kidney disease (CKD) progression and 
highest levels are found in patients with CKD stage V. Our recent work indicates that FGF23 levels begin to rise 
much earlier during CKD progression than previously appreciated, even before the establishment of clinically 
evident CKD15.
Thiazide diuretics act by blocking the thiazide-sensitive NaCl cotransporter (NCC), apically localized in epi-
thelial cells lining the distal convoluted tubule (DCT)7. Recent data suggest that FGF23 directly activates NCC 
in the DCT, thereby inducing volume expansion, hypertension, and subsequently left ventricular hypertrophy16. 
Interestingly, the thiazide diuretic hydrochlorothiazide prevented these presumed off target effects. Conversely, 
changes in volume status may modulate FGF23 concentrations, which is evident at least in patients undergo-
ing hemodialysis17. This suggests the presence of a feedback loop, where FGF23 increases volume load, and an 
increase in volume may reduce FGF23. Therefore, hypovolemia may in turn increase FGF23.
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Loss-of- function mutations in NCC cause Gitelman’s syndrome (OMIM 263800), a condition characterized 
by sodium wasting and hypotension8,9. Extracellular volume is decreased and aldosterone levels are increased 
by either pharmacological inhibition or genetic deletion of NCC8,9,18,19. Aldosterone upregulates FGF23 levels in 
osteoblasts20. Aldosterone is in part effective by augmenting store operated Ca2+ entry (SOCE) with subsequent 
increase of cytosolic Ca2+ 21, a powerful stimulator of FGF23 transcription22. The aldosterone-mediated FGF23 
release presumably contributes to the up-regulation of FGF23 plasma concentration by salt depletion20, lith-
ium treatment23, non-ischemic cardiac disease10 and early chronic kidney disease10. With these considerations in 
mind, we hypothesized that NCC activity modulates circulating FGF23 levels indirectly via extracellular volume 
and aldosterone secretion.
Results
NCC KO mice exhibit higher circulating FGF23 levels and higher FGF23 transcript in bone. We 
first measured mineral metabolism markers in WT and NCC KO mice. To this end, both C-terminal FGF23 
(cFGF23) and intact FGF23 (iFGF23) levels were determined by ELISA. As shown in Fig. 1, the cFGF23 and 
iFGF23 levels were significantly higher in NCC KO mice than in WT mice on standard rodent chow. Both 
cFGF23 and iFGF23 were elevated to a similar degree. We also observed a significant increase of PTH in NCC KO 
mice compared to WT mice. 1,25(OH)2D3 levels, however, were similar in both groups of mice.
Bone is the primary site of FGF23 formation. Therefore, FGF23 transcript levels were quantified in femora 
of WT and NCC KO mice. As shown in Fig. 2, FGF23 mRNA was significantly higher in NCC KO mice than 
littermate WT mice.
Phosphate homeostasis is unaltered in NCC KO mice. We next sought to determine the impact of ele-
vated FGF23 levels on calcium and phosphate homeostasis. As illustrated in Fig. 3, serum phosphate and calcium 
concentrations were not significantly different between NCC KO mice and WT mice. As previously reported24, 
Figure 1. Blood concentrations of cFGF23, iFGF23, PTH and 1,25(OH)2D3 in WT and NCC KO mice. 
Arithmetic means ± SEM (n = 9–12) of serum cFGF23 (a), serum iFGF23 (b), plasma PTH (c) and serum 
1,25(OH)2D3 (d) in WT (grey bars) and NCC KO (black bars) under normal diet. *(p < 0.05) indicates 
significant difference from NCC WT mice.
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the serum magnesium concentration was found to be significantly reduced in NCC KO mice. Absolute urinary 
phosphate and magnesium excretion were similar in NCC KO and WT mice, whereas the urinary calcium excre-
tion was significantly lower in NCC KO mice. Fractional excretion (FE) of calcium was significantly lower (WT: 
0.56 ± 0.08%; KO: 0.30 ± 0.05%; p = 0.010) and FE of magnesium was significantly higher in NCC KO mice (WT: 
20.13 ± 1.67%; KO: 28.14 ± 3.09%; p = 0.029). No significant difference was observed in FE of phosphate between 
the two genotypes of mice (WT: 19.72 ± 1.80%; KO: 21.39 ± 2.13%; p = 0.553).
To assess if higher FGF23 levels affect the apical abundance of proximal tubular NaPi2a, we isolated brush 
border membrane vesicles (BBMV) from NCC WT and KO mice and immunoblotted for NaPi2a. As shown 
in Fig. 4a, NaPi2a expression in BBMVs isolated from NCC KO mice and WT mice were similar. We next also 
assessed expression of FGFR1 and its co-receptor α-Klotho in NCC WT and KO total kidney lysates. As illus-
trated in Fig. 4b, expression of α-Klotho and FGFR1 were similar in kidneys of both groups of mice.
Inhibition of NCC does not cause an increase FGF23 transcript in primary osteoblasts. NCC 
is expressed in osteoblasts25,26 and therefore may contribute to the regulation of FGF23 release. To explore this 
possibility, we tested whether the NCC inhibitor hydrochlorothiazide was able to up-regulate FGF23 transcript 
levels in primary murine osteoblasts. We isolated primary osteoblasts from neonatal murine calvaria. Primary 
osteoblasts were treated with vehicle (negative control), 10 nM 1,25(OH)2D3, (positive control) or three different 
concentrations of the thiazide diuretic hydrochlorothiazide (1, 10 or 100 µM) for 24 hrs. As illustrated in Fig. 5, 
FGF23 transcript was significantly upregulated by 1,25(OH)2D3 treatment. In contrast, FGF23 mRNA remained 
unchanged following treatment with 1 µM or 100 µM hydrochlorothiazide, whereas 10 µM hydrochlorothiazide 
caused a small decrease. Hence, increased circulating FGF23 levels in NCC KO mice seem not to be due to NCC 
deficiency in FGF23 producing osteoblasts.
Mineralocorticoid receptor blockade reduces FGF23 levels in NCC KO but not WT mice. Under 
regular chow diet, aldosterone levels are higher in NCC KO mice (Fig. 6a). In order to test if aldosterone is 
mediating the elevation of FGF23 levels in NCC KO mice, we treated NCC WT and KO mice with the spe-
cific mineralocorticoid receptor blocker eplerenone for 7 days. Blood samples were taken prior and after the 
treatment. Serum aldosterone, cFGF23 and iFGF23 were measured. As expected, aldosterone levels were sig-
nificantly increased in both genotypes after eplerenone treatment (Fig. 6a). Eplerenone treatment significantly 
reduced cFGF23 and iFGF23 in NCC KO but did not affect FGF23 levels in WT mice (Fig. 6b,c). The difference 
in iFGF23 between WT and NCC KO mice was completely abolished by eplerenone treatment whereas cFGF23 
levels remained higher in NCC KO mice.
Effect of phosphate deficient diet on mineral metabolism in NCC KO mice. We next subjected 
WT and NCC KO mice to a phosphate deficient diet for a total of 5 days to create a negative phosphate balance 
and stress the phenotype of NCC KO mice. As shown in Fig. 7a–c, the phosphate deficient diet elicited in both 
genotypes a significant decrease of the serum phosphate concentration and a significant increase of the serum cal-
cium concentration. Serum magnesium was not significantly modified by a low phosphate diet. After a low phos-
phate diet, the difference in cFGF23 levels between WT and NCC KO mice disappeared, the absolute decrease 
Figure 2. FGF23 mRNA levels in femora of WT and NCC KO mice. Arithmetic means ± SEM (n = 6–8) of 
FGF23 mRNA levels in femora obtained from WT (black bars) and NCC KO mice (grey bars) under normal 
diet. **(p < 0.01) indicates significant difference from NCC WT mice.
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of cFGF23 in both groups of mice, however, was not significant (Fig. 7d). On the other hand, a low phosphate 
diet significantly decreased iFGF23 and PTH concentrations in both genotypes and dissipated the differences of 
iFGF23 and PTH between WT and KO mice (Fig. 7e,f). In both groups of mice, a low phosphate diet was followed 
by a sharp decline of urinary phosphate excretion and a marked increase of urinary calcium excretion (Fig. 7g,h). 
Urinary phosphate excretion was significantly lower in NCC KO mice on day 4 and 5 compared to NCC WT mice 
(Fig. 7g). Urinary calcium excretion remained significantly lower in NCC KO mice than in WT mice throughout 
the experiment. However, the difference between two genotypes was significantly amplified by a low phosphate 
diet (Fig. 7h).
Effect of phosphate deficient diet on serum aldosterone and electrolytes homeostasis. To 
explore if a low phosphate diet influences electrolyte homeostasis, serum and urinary sodium and potassium as 
well as aldosterone serum levels were determined at baseline and during the low phosphate diet. As shown in 
Fig. 8a, under a control diet, serum aldosterone was significantly higher in NCC KO mice compared to WT mice, 
as expected. Phosphate depletion induced an increase of serum aldosterone in both genotypes and dissipated the 
differences between the genotypes. Serum sodium and was not significantly different between the genotypes and 
was not significantly modified by a phosphate deficient diet (Fig. 8b). Urinary sodium excretion was significantly 
higher in NCC KO than WT mice at day one after initiation of a phosphate depleted diet (Fig. 8d). Phosphate 
depletion induced a significant increase of serum potassium in WT but not in NCC KO mice (Fig. 8c). Under low 
phosphate diet but not regular chow, NCC KO mice displayed reduced serum potassium compared to WT mice. 
The phosphate-deficient diet tended to decrease urinary potassium output in both genotypes, an effect, however, 
not reaching statistical significance (Fig. 8e). The urinary sodium to potassium ratio was similar in both groups 
of mice throughout the experiment (Fig. 8f).
Discussion
The present observations reveal that deficiency of distal tubular NCC elicits an increase of circulating FGF23. 
Increased FGF23 levels in NCC KO mice are not accompanied by a reduction of circulating 1,25(OH)2D3, renal 
phosphate reabsorption or brush border expression of the sodium/phosphate co-transporter 2 a, suggesting renal 
Figure 3. Blood and urinary phosphate (Pi), calcium (Ca) and magnesium (Mg) in WT and NCC KO mice. 
(a–c) Arithmetic means ± SEM (n = 9–12) of serum Pi (a), Ca (b) and Mg (c) in WT (black bars) and NCC KO 
mice (grey bars) under normal diet. (d–f) Arithmetic means ± SEM (n = 9–12) of urinary Pi (d), Ca (e) and Mg 
(f) normalized with creatinine in WT (black bars) and NCC KO mice (grey bars) under normal diet. *(p < 0.05) 
indicates significant difference from WT mice.
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resistance to the action of FGF23. Experiments with the mineralocorticoid receptor blocker eplerenone further-
more suggest that the observed increase in FGF23 levels in NCC KO mice is primarily a result of the volume 
depletion-induced secondary hyperaldosteronism.
Aldosterone works by up-regulating store operated Ca2+ entry (SOCE) with subsequent increase of cytosolic 
Ca2+ concentration20,21, a powerful stimulator of FGF23 transcription22. Renal tubular NaCl wasting and subse-
quent stimulation of aldosterone release possibly account further for the enhanced FGF23 levels in gene targeted 
mice expressing WNK-resistant SPAK27,28 or OSR129,30. FGF23 serum levels are increased in heart failure9,10, 
acute renal failure11, chronic kidney disease4,10,12, diabetic nephropathy13 and hepatic failure14. In each of these 
Figure 4. Brush border abundance of Napi2a and renal expression of α-Klotho and FGFR1. (a) Original 
western blot of Napi2a and beta actin in BBM isolated from NCC WT and KO kidneys. Quantification of 
Napi2a expression in WT and KO kidneys. (b) Original western blot of α-Klotho, FGFR1 and beta actin in total 
kidney lysate from NCC WT and KO kidneys. Quantification of α-Klotho and FGFR1 expression in WT and 
KO kidneys.
Figure 5. Effect of hydrochlorothiazide (HCT) treatment on FGF23 expression in murine primary osteoblast. 
Arithmetic means ± SEM (n = 5–6) of FGF23 mRNA levels in murine primary osteoblasts following treatment 
with vehicle (ethanol; control), 10 nM 1,25(OH)2D3 or 1, 10, 100 μM HCT. *(p < 0.05) for ctrl vs 1,25(OH)2D3, 
HCT 1, 10, 100 μM. FGF23 transcript levels are expressed relative to the level of the GAPDH control gene.
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6SCIENTIFIC RepoRts |  (2018) 8:3590  | DOI:10.1038/s41598-018-22041-1
disorders, serum aldosterone levels are increased31–37. Thus, secondary hyperaldosteronism may contribute to or 
even account for the increased serum FGF23 levels in these disorders. Our data strongly suggest that increased 
FGF23 levels are a consequence of increased aldosterone levels in NCC KO mice. Vitamin D levels are similar in 
WT and KO mice, hence vitamin D seems not to be an important driver of FGF23 secretion in NCC KO mice. 
However, we find that PTH is increased in NCC KO mice, as previously reported19. Since PTH38–40 also stimulates 
FGF23 secretion, PTH may contribute to the increase of FGF23 in NCC KO mice.
The receptors for angiotensin II (AT1 and AT2)41 and aldosterone (MR)42 are readily expressed in the bone, 
which is the main site of FGF23 production. Surprisingly, these hormones, which have hitherto been implicated 
in regulating volume regulation in mammals, also have a function in bone homeostasis. Aldosterone is at least 
in part effective by stimulation of mineralocorticoid receptors with subsequent up-regulation of the serum- and 
glucocorticoid-inducible kinase 1 (SGK1)20, which activates NFκB, a transcription factor stimulating the expres-
sion of the Ca2+ channel Orai143. Therefore, blocking of these receptors in NCC KO mice resulted in reversal of 
FGF23 phenotype. Wild type mice did not show significant reduction after blocking receptors indicating min-
eralocorticoid receptor blockers are effective reducing FGF23 levels only at pathological conditions (here higher 
aldosterone levels). NCC KO mice have activated renin-angiotensin-aldosterone axis24,44. At least in theory, it is 
possible that these hormones form a vicious cycle which may cause FGF23 upregulation in NCC KO mice. It will 
be interesting to analyze direct effects of renin/angiotensin on FGF23 levels in a separate study.
Several studies have previously shown NCC expression in osteoblasts or bone and suggested that inhibition 
of NCC activity may directly augment osteoblast differentiation25,26. In our study we have observed unchanged 
or even decreased transcript expression of FGF23 in primary osteoblasts following thiazide treatment. Therefore, 
our in-vitro data suggest that increased FGF23 levels in the serum of NCC KO mice are not merely a response of 
bone cells to direct NCC ablation but a consequence of lack of extra-osseous NCC activity.
To determine whether NCC KO mice adapt normally to a change from a normal-phosphate diet to a 
low-phosphate diet, animals were fed a low-phosphate diet for 5 days. There was, however, a marked alteration 
in hormone levels and mineral metabolism during the course of the low phosphate diet. Phosphate depletion led 
to a decline of serum phosphate concentration with enhanced calcium efflux from bone and increase of serum 
calcium concentration45. The hypercalcemia suppresses PTH release and thus abrogates the stimulatory effect of 
PTH on FGF23. The loss of PTH stimulation presumably accounts for the sharp decline of iFGF23 despite a fur-
ther increase of serum aldosterone levels. Therefore, it is tempting to speculate that the stimulation by PTH may 
be a prerequisite for the effect of aldosterone on FGF23.
Our study indicates that NCC is not only an important player in sodium and volume homeostasis but also 
in the regulation of mineral metabolism. Thiazides have been shown to preserve mineralization in long and 
axial bones46,47. The mechanism appears to be multifactorial involving effects on the kidneys, intestinal calcium 
absorption48,49 as well as bone remodeling25. Previous findings in NCC KO19,26 mice are consistent with a rand-
omized human trial showing hydrochlorothiazide treatment for 2 years decreased cortical bone loss in normal 
postmenopausal women46. Decreased urinary calcium output is a hallmark feature of thiazide treatment and 
could be explained by extracellular volume contraction with compensatory stimulation of NaCl and calcium 
reabsorption in proximal renal tubules and thick ascending limbs50. The current findings could also be of value in 
relation to mineral metabolism in human electrolyte disorders. Gitelman syndrome, a salt-wasting tubulopathy, 
is caused by mutations in the gene coding for the thiazide sensitive NCC8,9. The issue of renal phosphate wasting 
and hypophosphatemia has remained so far unrecognized with the exception of one controlled study and two 
case reports51–54. This is related to the fact that hypophosphatemia in these patients is very mild and physiological. 
Clearly, determinations of FGF23 and 1,25(OH)2D3 levels and a thorough investigation of renal phosphate han-
dling in Gitelman’s patients is needed to determine if lack of NCC activity causes a similar phenotype in humans 
as we have observed in NCC KO mice.
Figure 6. Effect of eplerenone on circulating aldosterone, cFGF23 and iFGF23 levels. (a–c) Arithmetic 
means ± SEM (n = 6–7) of serum aldosterone (a), serum cFGF23 (b), and serum iFGF23 (c) in NCC WT mice 
NCC KO under baseline and following oral eplerenone treatment for 7 days (right bars). *(p < 0.05) indicates 
significant difference from NCC WT mice, #(p < 0.05) indicates significant difference from eplerenone diet.
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Figure 7. Effect of dietary phosphate depletion on blood and urinary electrolytes and circulating cFGF23, 
iFGF23 and PTH levels in WT and NCC KO mice. (a–f) Arithmetic means ± SEM (n = 6–7) of serum 
phosphate (a), Ca (b) and Mg (c) levels. Serum cFGF23 (d), serum iFGF23 (e), and plasma PTH (f) in NCC 
WT mice (grey bars) and NCC KO (black bars) under normal diet (Ctrl diet, left bars) and following dietary 
phosphate depletion for 5 days (LPD, right bars). *(p < 0.05) indicates significant difference from NCC WT 
mice, #(p < 0.05) indicates significant difference from normal diet. (g,h) Arithmetic means ± SEM (n = 6–7) 
of urinary phosphate excretion (g) and urinary calcium excretion (h) in NCC KO and wild type mice under 
normal diet (Day 0) and following dietary phosphate depletion (Day 1–5). *(p < 0.05), **(p < 0.01) indicate 
significant difference from NCC WT mice.
www.nature.com/scientificreports/
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Methods
Unless specified otherwise, all chemicals and reagents were obtained from Sigma.
Animal experiments. Animal experiments were conducted according to the Swiss law for the welfare of 
animals and were approved by the Veterinary authority of the Kanton Bern (Amt für Landwirtschaft des Kantons 
Bern Veterinärdienst). Experiments were performed in NCC KO and WT littermate mice. Generation, charac-
teristics and genotyping of NCC KO have been described earlier24. Male age-matched mice (9–15 weeks old) were 
used for the experiments.
Mice had free access to control diet (Ssniff, Soest, Germany) containing 7000 mg/kg phosphorus or to 
phosphate-depleted diet (Altromin, Lage, Germany) containing 131 mg/kg phosphate and to tap water ad libitum. 
For blood draws, mice were anaesthetized with isoflurane (Roth, Karlsruhe, Germany) and blood was drawn into 
capillaries by puncturing the retrobulbar plexus. To measure urinary parameters, mice were placed individually 
in metabolic cages (Techniplast, Hohenpeissenberg, Germany) as described previously55. Mice were allowed a 
2 days habituation period during which food and water intake, urinary flow rate and phosphate excretion were 
recorded every day to ascertain that mice were adapted to the new environment. Subsequently, consecutive 24 h 
urine collections were performed. Urine was collected under water-saturated oil. Urinary electrolytes and creati-
nine measurements were done at the Central laboratory of the Bern University Hospital.
Eplerenone was purchased from the Bern University hospital pharmacy (Eplerenone-Mepha, Switzerland). 
Mice on standard chow diet received 50 mg/kg of eplerenone through oral gavage at 8am and 8 pm for 7 days.
Isolation and Culture of Primary Murine Osteoblasts. Primary osteoblasts were isolated from calvar-
iae of one- and two-day-old C57Bl/6J mice by sequential collagenase digestion, as described previously56. Briefly, 
5 calvariae were digested (5 × 20 min) in Hank’s Balanced Salt Solution (HBSS; Sigma, Buchs, CH) containing 
3 mg/ml collagenase II (Worthington, NJ, USA). Fractions 3–5 were pooled, and 106 cells were seeded into 75 cm2 
culture flasks and grown in culture medium containing αMEM (α-minimum essential medium) supplemented 
with 10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin at 37 °C in a humidified atmosphere with 5% 
CO2. After 4 days in culture, cells were stored in liquid nitrogen (106 cells/ml). Before use, cells were thawed, 
Figure 8. Effect of dietary phosphate depletion on blood and urinary electrolytes and circulating aldosterone 
levels in WT and NCC KO mice: (a–c) Arithmetic means ± SEM (n = 6–7) of serum aldosterone (a), Na (b) 
and K (c) levels in NCC WT mice (black bars) and NCC KO (grey bars) under normal diet (Ctrl diet, left 
bars) and following dietary phosphate depletion for 5 days (LPD, right bars). *(p < 0.05) indicates significant 
difference from NCC WT mice, #(p < 0.05) indicates significant difference from normal diet. (d–f) Arithmetic 
means ± SEM (n = 6–7) of urinary Na excretion (d) urinary K excretion (e) and the ratio of urinary Na to K 
excretion (f) in NCC KO and WT mice under normal diet (Day 0) and following dietary phosphate depletion 
(Day 1–5). *(p < 0.05) indicate significant difference from NCC WT mice.
www.nature.com/scientificreports/
9SCIENTIFIC RepoRts |  (2018) 8:3590  | DOI:10.1038/s41598-018-22041-1
grown in culture medium for 4 days, and used according to the experimental protocol; time periods for prepara-
tion and culture of primary calvarial osteoblasts were strictly adhered to.
BBMV isolation. Renal cortical BBMV were prepared by the Mg2+ aggregation method as previously 
described57. Briefly, frozen kidney cortical samples were homogenized in ice-cold isolation buffer (300 mM 
Mannitol, 5 mM EGTA and 18 mM HEPES with pH adjusted to 7.5 with 1 M Tris base) containing fresh protease 
inhibitors, and crude membranes were obtained by centrifugation at 48,000 g for 1 h at 2 °C. Pellets were resus-
pended, homogenized in a Dounce glass homogenizer, and subjected to Mg2+ aggregation by addition of MgCl2 
to a final concentration of 15 mM at 4 °C for 20 min. Aggregated membranes were removed by centrifugation at 
3,000 g for 10 min at 2 °C and the supernatant was subjected to two additional rounds of Mg2+ aggregation as 
above, followed by centrifugation at 48,000 g for 30 min at 2 °C. The resulting pellet enriched in BBMV was dis-
solved in 200 µl ice-cold RIPA buffer. Total membrane fractions were prepared from frozen kidneys after homog-
enization in freshly made membrane preparation buffer (200 mM mannitol, 80 mM HEPES, 41 mM KOH, and 1 
dissolved Complete Protease Inhibitor tablets, (Roche Diagnostics) using a homogenizer. The homogenate was 
then centrifuged for 15 min at 4 °C and 2,600 g, and the resulting supernatant was placed in an ultracentrifuge 
(Beckman ultracentrifuge tubes) for 1 h at 100,000 g and 4 °C. The pellet was resuspended in resuspension buffer, 
and protein concentration was quantified using a colorimetric assay (DcProtein Assay, Bio-Rad). 40 μg of dis-
solved BBMV protein or total kidney membrane protein were then used for separation by SDS-PAGE.
Immunoblotting. Total protein (40 µg) was loaded on 8% v/v gels for protein separation by SDS-PAGE, 
followed by transfer to polyvinylidene difluoride (PVDF) membranes (Immobilon-P, Millipore Corporation, 
Bedford, MA, USA). Membranes were incubated overnight at 4 °C with primary antibodies. After washing, 
PVDF membranes were incubated with the appropriate secondary antibodies for one hour at room temperature. 
Immunoreactive bands were visualized using chemiluminescence (Amersham ECL, GE healthcare life sciences). 
Densitometric analysis was performed using ImageJ software (NIH, USA).
Antibodies. The following primary antibodies were used: Polyclonal rabbit anti-NaPi-IIa 1:2,000, obtained 
from Prof. Biber J (University of Zurich)58. Polyclonal anti-actin (Santa Cruz Biotechnology, Santa Cruz, CA, 
1:5000). FGFR1 mAb 9740: Cell Signaling (1:1000). Klotho MAb KM2076: Vendor Transgenics (1:2000). 
Secondary antibodies used were peroxidase-conjugated (Sigma-Aldrich, St. Louis, MO, USA; 1:20000).
Total RNA isolation and cDNA synthesis. Total RNA was isolated from approximately 2 million cells 
using a Total RNA Mini Kit (Bio-Rad, Hercules, CA) according to the manufacturer’s protocol. First strand cDNA 
was synthesized from 2 μg of RNA using an iScript kit (Bio-Rad, Hercules, CA) according to the manufacturer’s 
instructions in 40 μl total volume.
Quantification of mRNA expression. Quantitative real time PCR (qrtPCR) was performed with Applied 
Biosystems SYBR Green 2 × PCR Master Mix (Life Technologies, Carlsbad CA) in a System 7500 Fast thermal 
cycler using 1.5 μl of first strand DNA and 0.5 μl of 18 μM primer mixture in 10 μl total volume per well in dupli-
cate. Reactions were performed in 384-well PCR plates and read on an ABI 7500 Fast instrument.
Mouse Fgf23 primers used were. forward (5′-3′): TTTCCCAGGTTCGTCTAG
reverse (5′-3′): CTCGCAGGTGACTCT
Mouse GAPDH primers used were. forward (5′-3′): TAACATCAAATGGGGTGA
reverse (5′-3′): GGTTCACACCCATCACAA
Calculated mRNA expression levels were normalized to the expression levels of GAPDH of the same cDNA 
sample. Relative quantification of gene expression was performed using the ΔCt method.
Hormone measurements. Serum C-terminal-FGF23 and serum intact FGF23 (Immutopics International, 
San Clemente, CA, USA and Kainos laboratories, Japan respectively), serum 1,25(OH)2D3 (IDS, Boldon, UK), 
plasma intact PTH (1–84) (Immutopics, San Clemente, USA) and serum aldosterone (IBL, Hamburg, Germany) 
concentrations were measured by ELISA or EIA according to the manufacturer’s instructions.
Statistics. Data are provided as means ± SEM, n represents the number of independent experiments. 
Statistical analysis was done using Student´s t test or one-way analysis of variance (ANOVA) with Tukey post-hoc 
test to correct for multiple comparisons, as appropriated. All statistical tests were two-sided and a P value < 0.05 
was considered statistically significant.
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